Cartography Biosciences, a San Francisco Bay Area biotechnology company, announced Thursday it raised a $67 million Series B round to propel its first drug prospect into clinical testing. Its lead ...

Financing led by Pfizer Ventures will support advancement of lead program CBI-1214 into a Phase 1 trial, targeted for enrollment in early 2026, and expand next wave of programs from the ATLAS and ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, an immuno-oncology company creating biologic therapies against novel targets guided by the first-ever comprehensive antigen atlas ...

Collaboration leverages Cartography’s cutting-edge ATLAS and SUMMIT platforms to identify tumor-selective antigens; Pfizer to lead therapeutic development –– Cartography to receive upfront, near-term ...